Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early evolocumab in acute myocardial infarction
ChiCTR2600133435Phase 4Not yet recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in myocardial infarction (MI) (2 arms), sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Primary endpoints: Interleukin-1 beta at day 14, NLRP3 at day 14 and 6 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2600133435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133435.